

Declaration under 37 CFR 1.132
USSN 10/650,931

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of _____ Docket No: Q110631

Jong-Soo WOO, et al.

Appln. No.: 10/650,931 _____ Group Art Unit: 1614

Confirmation No.: 8064 _____ Examiner: SPIVACK, PHYLLIS G

Filed: August 27, 2003

For: SUSTAINED RELEASE COMPOSITION FOR ORAL ADMINISTRATION OF DRUGS

DECLARATION UNDER 37 C.F.R. § 1.132


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Jong-Soo Woo, hereby declare that I am the same individual who executed the

Declaration under 37 C.F.R. 1.132 filed in the present application on June 18, 2007.

In addition, the applicants conducted additional in vitro release-tests for the formulations of Examples 3 and 5 comprising isradipine and glypizide, respectively, by employing the same procedure of Test Example 1 described in the subject application, and the results are shown below:



As can be seen from the test results, each of the formulations comprising isradipine and glypizide releases the drug at a constant release rate following zero order kinetics for 24 hours.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

Jong-Soo Woo